Key facts
| Price (PPV) | 5,625 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | faricimab |
| Class | Ophthalmologicals |
| ATC code | S01LA09 |
| Manufacturer | ROCHE S.A |
| Presentation | Boite d'un flacon de 0,24ml avec une auguille-filtre |
| Hospital price | 5,378 MAD |
| Data collected on | 9/8/2026 |
Indications
Traitement de la forme néovasculaire (humide) de la dégénérescence maculaire liée à l'âge (DMLAn). Traitement de l'œdème maculaire diabétique (OMD). Traitement d'un œdème maculaire secondaire à une occlusion veineuse rétinienne (occlusion d'une branche veineuse rétinienne [OBVR] et occlusion de la veine centrale de la rétine [OVCR]). Source : Compendium.ch - Date : 20 octobre 2025
Find an open pharmacy
On-call pharmacies near you
About Vabysmo 28.8 mg / 0.24 ml
Vabysmo 28.8 mg / 0.24 ml belongs to the ophthalmologicals therapeutic class. In Morocco, this drug is marketed by ROCHE S.A and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Vabysmo 28.8 mg / 0.24 ml, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Vabysmo 28.8 mg / 0.24 ml
Answers to common questions from Moroccan patients about this drug.